[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-pseudocyst\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-pseudocyst":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,67,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100529875","registry-of-patients-undergoing-endoscopic-management-of-pancreatic-fluid-collections-100529875",false,"NCT06179459","Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections","Inclusion Criteria:\n\n* Age ≥ 18 years\n* All patients undergoing endoscopic treatment of pancreatic fluid collections\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Patients who did not receive endoscopic treatment of pancreatic fluid collections","ALL","18 Years",{"count":18,"type":19},1000,"ESTIMATED","OBSERVATIONAL","Acute pancreatitis is one of the most common gastrointestinal disorders requiring hospitalization worldwide. Pancreatic fluid collections can occur as a consequence of acute and chronic pancreatitis and can result in significant morbidity and mortality, including significant abdominal pain, gastric outlet obstruction, biliary obstruction, organ failure, persistent unwellness, infection and sepsis.\n\nSymptomatic pancreatic fluid collections require treatment, and endoscopic drainage is considered standard of care. The aim of this study is to evaluate the treatment outcomes in patients undergoing standard of care, endoscopic treatment of pancreatic fluid collections.",[23,24,25],"Acute Pancreatitis","Pancreatic Pseudocyst","Pancreatic Necrosis","RECRUITING","2025-11-03",{"date":29,"type":30},"2025-11-04","ACTUAL",{"date":32,"type":30},"2021-05-01",{"date":34,"type":19},"2032-12",{"name":36,"class":37},"Orlando Health, Inc.","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":38},"100581836","efficacy-and-safety-of-hanarosten-hot-plumber-with-z-eusit-for-pancreatic-pseudocyst-drainage-100581836","NCT06855485","Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocyst Drainage","A Prospective Single-Center Observational Study on the Evaluation of Efficacy and Safety of HANAROSTEN® HOT Plumber™ With Z-EUSIT™ for Pancreatic Pseudocysts Drainage","ZEUS","Inclusion Criteria:\n\n* Must be 18 years or older\n* Diagnosed with pancreatic or peripancreatic pseudocyst or walled-off necrosis (with less than 30% solid components)\n* Eligible for endoscopic ultrasound-guided drainage\n* Able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* Pseudocysts with the following characteristics:\n* Immature pseudocyst\n* Cystic neoplasm\n* Pseudoaneurysm\n* Multiple pseudocysts requiring drainage\n* Uncontrolled coagulation disorders:\n* INR \\> 1.5\n* Platelet count \\\u003C 50,000\u002Fmm³\n* Other bleeding disorders\n* Ineligibility for EUS-guided drainage due to anatomical or technical reasons\n* History of anaphylactic reaction to stent materials\n* Pregnant or potentially pregnant women\n* Current participation in another clinical trial that may affect study outcomes",{"count":48,"type":19},20,"INTERVENTIONAL",[51],"NA","The goal of this prospective, single-center observational study is to evaluate the safety and effectiveness of the HANAROSTEN® HOT Plumber™ with Z-EUSIT™ for draining pancreatic pseudocysts.\n\nThe main questions the study aims to answer are:\n\n* Does the device reduce the size of pancreatic pseudocysts by at least 50% and improve associated symptoms within 30 to 60 days?\n* Can the stent be successfully placed, retained, and removed without complications?\n\nParticipants will:\n\n* Undergo endoscopic ultrasound-guided transgastric or transduodenal drainage of pancreatic pseudocysts using the HANAROSTEN® HOT Plumber™ with Z-EUSIT™.\n* Be monitored for adverse events such as bleeding, infection, stent migration, or tissue injury.\n* Return for follow-up visits within 30 or 60 days for stent removal and evaluation of clinical success.\n\nThe study will:\n\n* Enroll 20 adults aged 18 years or older who meet the inclusion criteria.\n* Conduct follow-up assessments until one month after stent removal.",[24],[24,55,56,57],"Endosonography","Drainage","Stents","2025-02-27",{"date":60,"type":30},"2025-03-03",{"date":62,"type":19},"2025-02-25",{"date":64,"type":19},"2025-12-30",{"name":66,"class":37},"Asan Medical Center",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":49,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100526306","wonder-02-trial-plastic-stent-vs-lumen-apposing-metal-stent-for-pancreatic-pseudocysts-100526306","NCT06133023","WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts","WONDER-02: Plastic Stent vs. Lumen-apposing Metal Stent for Endoscopic Ultrasound-guided Drainage of Pancreatic Pseudocysts-a Multicentre Randomised Non-inferiority Trial","Inclusion Criteria:\n\n* Patients with pancreatic pseudocyst(s) defined by the revised Atlanta classification\n* The longest diameter of a targeted pseudocyst ≥ 5 cm\n* Patients requiring drainage for symptoms associated with a pseudocyst (e.g., infection, gastrointestinal symptoms including abdominal pain, or jaundice)\n* Patients aged 18 years or older\n* Written informed consent obtained from patients or their representatives\n\nExclusion Criteria:\n\n* A pseudocyst that is inaccessible via the EUS-guided approach\n* A plastic or lumen-apposing metal stent in situ\n* Coagulopathy (e.g., platelet count \\\u003C 50,000\u002Fmm3 or prothrombin time international normalised ratio \\[PT-INR\\] \\>1.5)\n* Users of antithrombotic agents that cannot be discontinued according to the Japan Gastroenterological Endoscopy Society \\[JGES\\] guidelines\n* Patients who do not tolerate endoscopic procedures\n* Pregnant women",{"count":75,"type":19},80,[51],"Endoscopic ultrasound (EUS)-guided transluminal drainage has become a first-line treatment modality for symptomatic pancreatic pseudocysts. Despite the increasing popularity of lumen-apposing metal stents (LAMSs), the use of a LAMS is limited by its high costs and specific adverse events compared to plastic stent placement. To date, there has been a paucity of data on the appropriate stent type in this setting. This trial aims to assess the non-inferiority of plastic stents to a LAMS for the initial EUS-guided drainage of pseudocysts.",[79,80,24],"Pancreatic Fluid Collection","Pancreatitis",[55,56,57,24],"NOT_YET_RECRUITING","2023-11-09",{"date":85,"type":30},"2023-11-15",{"date":87,"type":19},"2023-11",{"date":89,"type":19},"2033-09",{"name":91,"class":37},"Tokyo University",26,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":49,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},"100473977","immediate-necrosectomy-vs-step-up-approach-for-walled-off-necrosis-100473977","NCT05451901","Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis","Immediate Necrosectomy vs. Step-up Approach After EUS-guided Drainage of Walled-off Necrosis: a Multicenter Randomized Controlled Trial (WONDER-01)","WONDER-01","Inclusion Criteria:\n\n* Patients with WON defined according to the revised Atlanta classification\n* The longest diameter of WON is 4 cm or larger\n* Patients with at least one out of the following conditions; signs of infection, gastrointestinal symptoms, abdominal symptoms, obstructive jaundice\n* Patients who need drainage for WON\n* Age of 18 years or older\n* Patients or their representatives provide informed consent\n* Patients who visit or are hospitalized at the participating institutions\n\nExclusion Criteria:\n\n* WON inaccessible by EUS-guided approach\n* AXIOS stent has already been placed into the WON prior to the enrollment\n* Severe coagulopathy; Platelet count \\\u003C 50,000\u002Fmm3 or prothrombin time international normalized ratio (PT-INR) \\>1.5\n* Patients on antithrombotic agents which cannot be managed according to the \"guideline for gastroenterological endoscopy in patients undergoing antithrombotic treatment (Dig Endosc. 2014 Jan;26(1):1-14.)\"\n* Patients who cannot tolerate endoscopic procedures\n* Pregnant women\n* Patients considered inappropriate for inclusion by investigators",{"count":102,"type":19},70,[51],"Walled-off necrosis (WON) is a pancreatic fluid collection, which contains necrotic tissue after four weeks of the onset of acute pancreatitis. Interventions are required to manage patients with infected WON, for which endoscopic ultrasonography (EUS)-guided drainage has become a first-line treatment modality. For patients who are refractory to EUS-guided drainage, the step-up treatment including endoscopic necrosectomy (EN) and\u002For additional drainage is considered to subside the infection. Recent evidence suggests that EN immediately after EUS-guided drainage may shorten treatment duration without increasing adverse events. In this randomized trial, the investigators will compare treatment duration between EN immediately after EUS-guided drainage versus the step-up approach in patients with symptomatic WON.",[79,106,107,24],"Walled-off Necrosis","Pancreatitis, Acute Necrotizing",[55,56,57,109,110],"Endoscopic necrosectomy","Step-up approach","2022-10-26",{"date":113,"type":30},"2022-10-27",{"date":115,"type":30},"2022-07-29",{"date":117,"type":19},"2031-04-11",{"name":91,"class":37},21]